{{drugbox
| verifiedrevid = 457129529
| IUPAC_name = N-(4-(acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide
| image = Amsacrine.svg
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 00DPD30SOY
| smiles = O=S(=O)(Nc1ccc(c(OC)c1)Nc2c4c(nc3c2cccc3)cccc4)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XCPGHVQEEXUHNC-UHFFFAOYSA-N
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 51264-14-3
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 43
| ATC_prefix = L01
| ATC_suffix = XX01
| ATC_supplemental = 
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 2687
| PubChem = 2179
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2094
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00276
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02321
| C=21 | H=19
| N=3 | O=3
| S=1
| molecular_weight = 393.46 g/mol
| bioavailability = 
| protein_bound = 96 to 98%
| metabolism = 
| elimination_half-life = 8–9 hours
| excretion = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status = 
| routes_of_administration = 
}}
'''Amsacrine''' (synonyms: m-AMSA, acridinyl anisidide) is an [[antineoplastic]] agent. 

It has been used in [[acute lymphoblastic leukemia]].<ref>{{cite journal | pmid = 16330449 | volume=90 | issue=12 | title=Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children |date=December 2005 | journal=Haematologica | pages=1701–3}}</ref>

==Mechanism==
Its planar fused ring system can [[intercalation (biochemistry)|intercalate]] into the [[DNA]] of [[tumor]] cells, thereby altering the major and minor groove proportions. These alterations to DNA structure inhibit both DNA replication and transcription by reducing association between the affected DNA and: DNA polymerase, RNA polymerase and transcription factors.

Amsacrine also expresses [[topoisomerase inhibitor]] activity, specifically inhibiting topoisomerase II (compares with the better known agent [[etoposide]]).<ref>Genetic Response to Metals. Sarkar, Bibudhendra. CRC Press, 1995. {{ISBN|978-0-8247-9615-0}}</ref> In contrast, the structurally similar o-AMSA differing in the position of the methoxy substituent group on the anilino-ring have little ability to poison topoisomerase II despite of its intercalative behavior, suggesting that intercalation of the molecule in itself is insufficient to trap topoisomerase II as a covalent complex on DNA. <ref>{{cite journal | pmid = 2602146 | pmc=335223 | volume=17 | issue=23 | title=Thermodynamics of the interactions of m-AMSA and o-AMSA with nucleic acids: influence of ionic strength and DNA base composition |date=December 1989 | journal=Nucleic Acids Res. | pages=9933–46 | doi=10.1093/nar/17.23.9933}}</ref> <ref>{{cite journal | pmid = 2830452 | volume=2 | issue=5 | title=Mutagenicity of m-AMSA and o-AMSA in mammalian cells due to clastogenic mechanism: possible role of topoisomerase |date=September 1987 | journal=Mutagenesis | pages=349–55 | doi=10.1093/mutage/2.5.349}}</ref>  <ref>{{cite journal | doi = 10.1038/nrc2607 | pmid = 19377506 | pmc=2748742 | volume=9 | issue=5 | title=Targeting DNA topoisomerase II in cancer chemotherapy |date=May 2009 | journal=Nat. Rev. Cancer | pages=338–50}}</ref>

==References==
<references/>


 
{{Chemotherapeutic agents}}

[[Category:Sulfonamides]]
[[Category:Antineoplastic drugs]]
[[Category:IARC Group 2B carcinogens]]
[[Category:Acridines]]
[[Category:O-Methylated phenols]]
[[Category:DNA intercalaters]]


{{antineoplastic-drug-stub}}